Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Martin, D. Articles by Brodeur, B. R. Search for Related Content PubMed PubMed Citation Articles by Martin, D. Articles by Brodeur, B. R.

 Previous Article  |  Next Article 

Infection and Immunity, September 2002, p. 4897-4901, Vol. 70, No. 9
0019-9567/02/$04.00+0     DOI: 10.1128/IAI.70.9.4897-4901.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Protection from Group B Streptococcal Infection in Neonatal Mice by Maternal Immunization with Recombinant Sip Protein

Denis Martin,^* Stéphane Rioux, Edith Gagnon, Martine Boyer, Josée Hamel, Nathalie Charland, and Bernard R. Brodeur

Unité de Recherche en Vaccinologie, Centre Hospitalier Universitaire de Québec et Université Laval, Ste-Foy, Canada G1V 4G2

Received 28 February 2002/ Returned for modification 8 April 2002/ Accepted 29 May 2002

Top Abstract Introduction Materials and Methods Results Discussion References

 
The protective potential of antibodies directed against group B streptococcus (GBS) Sip surface protein was determined by using the mouse neonatal infection model. Rabbit Sip-specific antibodies administered passively to pregnant mice protected their pups against a GBS lethal challenge. In addition, active immunization with purified recombinant Sip protein of female CD-1 mice induced the production of specific antibodies that also confer protection to the newborn pups against GBS strains of serotypes Ia/c, Ib, II, III, and V. These data confirm that Sip-specific antibodies can cross the placenta and conferred protective immunity against GBS infections.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Group B streptococcus (GBS) is the leading cause of life-threatening bacterial infections in newborns (28). Vaccination of pregnant women or women of reproductive age is often reported as being the best long-term preventive measure that could be developed against GBS infection (10, 21, 28). Already, several GBS capsular polysaccharide (CPS) types have been tested as vaccines in human adult volunteers (1, 3, 7). They were shown to be safe, but their immunogenicity was disappointing (3, 7). These CPS, when coupled to carrier proteins such as tetanus toxoid, were shown to be more immunogenic in preclinical animal assays (15, 20, 24, 25, 30-32) and human clinical trials (5, 6, 13), and as expected, the protection was shown to be type specific (3, 12, 13). Based on the current information on serotype distribution, a conjugate vaccine would have to include types Ia, Ib, II, III, and V to prevent the majority of disease in North America. However, the formulation would have to be modified to be effective in other parts of the world, such as Japan, where other serotypes, such as VI and VIII, are more prevalent (14).

Noncapsular surface antigens are being investigated as potential vaccine candidates or carrier proteins (11, 29). One of these noncapsular antigens, the Sip protein, was found to be highly conserved and produced by every GBS strain examined to date, which included representative isolates of all serotypes (8). It was also established that Sip-specific antibodies recognized their epitopes at the cell surfaces of different GBS strains (26). More importantly, the immune response to purified recombinant Sip protein (rSip) efficiently protected adult mice against experimental infection with GBS strains representing serotypes Ia/c, Ib, II/R, III, V, and VI (8). It was also found that humans exposed to GBS developed a specific antibody response against the Sip protein. Indeed, this protein was identified after the immunoscreening of a GBS genomic library with a pool of normal human adult sera (8). Although these studies suggested that these Sip-specific antibodies could play a role in the prevention of GBS infection, it is essential to clearly establish a direct link between the presence of Sip-specific antibodies and protection of neonates. In this study, we verified that the rSip protein could protect against GBS infection by using the mouse neonate model, which simulates human disease (22, 27).

Top Abstract Introduction Materials and Methods Results Discussion References

 
GBS strains. The GBS strain C388/90 (Ia/c) was isolated from the cerebrospinal fluid of a child with meningitis and was obtained from the Children's Hospital of Eastern Ontario (Ottawa, Ontario, Canada). The strains NCS 251 (II/c) and NCS 535 (V) were, respectively, isolated from joint fluid and blood samples from adult patients. Strain NCS 437 (III/R) was isolated from the blood of an infant. The latter three strains were generously provided by the National Centre for Streptococcus, Provincial Laboratory of Public Health for Northern Alberta (Edmonton, Alberta, Canada). The GBS strain ATCC 12401 (Ib) was obtained from the American Type Culture Collection (Manassas, Va.). The GBS strains were grown overnight on tryptic soy agar plates containing 5% (vol/vol) sheep blood (Quelab Laboratories, Montreal, Quebec, Canada) or in Todd-Hewitt broth (Difco Laboratories, Detroit, Mich.) at 37°C in the presence of 8% CO₂. Strains were stored at -80°C in brain heart infusion broth (Difco) containing 20% (vol/vol) glycerol (Sigma Chemical Co., St. Louis, Mo.).

Production and purification of recombinant Sip protein. The purified recombinant plasmid pURV32 (8) was used to transform Escherichia coli strain BLR (Novagen, Inc., Madison, Wis.) by electroporation with the Gene Pulser II apparatus (Bio-Rad Laboratories, Hercules, Calif.) following the manufacturer's recommendations. This recombinant strain was inoculated in Luria-Bertani broth (Gibco-BRL, Gaithersburg, Md.) containing 40 µg of kanamycin per ml (Sigma), and incubated at 34°C for approximately 3 h with agitation (optical density at 600 nm [OD₆₀₀] = 0.6), after which time, the temperature was increased to 39°C for 4 to 5 h in order to induce the production of the recombinant protein. After the induction period, the bacterial cells were removed from the culture media by centrifugation at 12,000 x g for 30 min at 4°C. The supernatant was then filtered onto a 0.22-µm-pore-diameter membrane and concentrated with an ultrafiltration apparatus and a Diaflo ultrafiltration membrane YM 10 (Amicon, Inc., Beverly, Mass.). The concentrated supernatant was submitted to 50% (wt/vol) ammonium sulfate precipitation, and the precipitated proteins were collected by centrifugation and suspended in 50 mM Tris-HCl buffer (pH 8.5). The rSip protein was purified by two successive chromatographic steps: first by hydrophobic interaction chromatography with Sepharose HP (Amersham Pharmacia Biotech, Baie d'Urfé, Quebec, Canada) and then by anionic-exchange chromatography with Hi-load Q-Sepharose high-performance resin (Amersham Pharmacia Biotech). The purity of the rSip protein was evaluated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and quantified by the bicinchoninic acid assay according to the manufacturer's instructions (Pierce Chemical Company, Rockford, Ill.).

Immunization and protection model. A 2.5-kg (body weight) New Zealand White female rabbit (Charles River Laboratories, St-Constant, Quebec, Canada) was immunized subcutaneously (s.c.) three times at 3-week intervals at several sites on the back with 100 µg of rSip protein in the presence of Freund's complete and incomplete adjuvant (Gibco-BRL). Serum samples were collected before the first immunization and again 2 weeks after the last immunization. The antibodies present in the serum samples were partially purified by ammonium sulfate precipitation followed by extensive dialysis against phosphate-buffered saline (PBS).

Female CD-1 mice (Charles River Laboratories), 5 to 7 weeks old, were injected s.c. three times at 3-week intervals with either 20 µg of purified rSip protein in 0.1 ml of PBS mixed with 20 µg of QuilA adjuvant (Cedarlane Laboratories, Hornby, Ontario, Canada) or 20 µg of QuilA in PBS as a negative control. Serum samples from each mouse were taken before each immunization and the day the challenge was performed. At the end of the immunization period, the mice were mated. For passive immunization, pregnant mice were injected intravenously (i.v.) with 500 µl of partially purified rabbit anti-Sip serum or the corresponding preimmune serum on day 16 of gestation. The mouse neonatal model of infection was adapted from that of Rodewald et al. (27). The bacterial challenges were performed between 9 to 14 weeks after the third immunization. The challenge dose, which varied between 4 x 10⁴ and 8 x 10⁵ CFU, depending on the GBS strain, was administered to the pups s.c. between 24 and 48 h after birth. To enhance virulence, GBS strains were passaged by intraperitoneal (i.p.) injection several times in female CD-1 mice as described by Lancefield et al. (16), and early-exponential-phase stock cultures were frozen at -80°C in brain heart infusion broth containing 20% glycerol. The GBS strains C388/90 (Ia/c), ATCC 12401 (Ib), NCS 251 (II/c), NCS 437 (III/R), and NCS 535 (V), respectively, were passaged 6, 8, 7, 11, and 5 times in CD-1 mice before they were used to challenge the mice. The 100% lethal doses (LD₁₀₀s) required to kill all animals were estimated to be 4 x 10⁴, 8 x 10⁵, 6 x 10⁴, 6 x 10⁴, and 8 x 10⁵ CFU, respectively, for the GBS strains C388/90 (Ia/c), ATCC 12401 (Ib), NCS 251 (II/c), NCS 437 (III/R), and NCS 535 (V). Mortality was recorded daily for the next 7 days. Statistical significance was estimated by Fisher's exact test.

Analysis of the mouse sera. Determination of Sip-specific antibody titers in the sera collected from dams and selected pups in the litters were determined by enzyme-linked immunosorbent assay (ELISA). Briefly, 100 µl of carbonate buffer (15 mM Na₂CO₃, 35 mM NaHCO₃ [pH 9.6]) containing purified rSip protein at a concentration of 1 µg/ml was added to each well of a flat-bottom microtitration plate (Falcon 3415; Becton Dickinson, Franklin Lakes, N.J.) and incubated overnight at room temperature. The plate was washed three times with PBS containing 0.05% (vol/vol) Tween 20. The mouse sera were serially diluted in PBS-Tween buffer, and 100 µl of each dilution was added to the appropriate well. The plate was incubated for 90 min at room temperature and then washed three times with PBS-Tween buffer. One hundred microliters of horseradish peroxidase-conjugated goat anti-mouse immunoglobulin G (IgG) (Kirkegaard & Perry Laboratories, Gaithersburg, Md.) diluted in PBS-Tween buffer was added to each well, and the plate was incubated for 60 min at room temperature. The plates were washed three times, 100 µl of tetramethylbenzidine substrate (Kirkegaard & Perry Laboratories) was added, and this mixture was then incubated for 10 min at room temperature. The reaction was stopped by the addition of 100 µl of 1 M phosphoric acid. The OD₄₅₀ was read with a SpectraMax 340 (Molecular Devices Corporation, Sunnyvale, Calif.) microplate reader. A pool of high-responder mouse antisera was assigned a Sip-specific arbitrary antibody unit (AU) value of 1,000 AU/ml and was used as the reference standard. For each serum, the optical values were transformed into AU per milliliter by using a reference standard curve calculated from the values obtained for the reference serum. A modified ELISA was used to evaluate the transfer of rabbit antibodies from the dams to their litters. In this assay, a goat alkaline phosphatase-labeled anti-rabbit IgG (Jackson ImmunoResearch Laboratories, Mississauga, Ontario, Canada) and p-nitrophenylphosphate disodium substrate (Sigma) were used instead of the previously described reagents. The serum dilution for which an absorbance reading of 0.1 ( = 405/630 nm) was recorded after background subtraction was considered the titer of this serum. Immunoblots with purified recombinant protein were performed as described previously (8). The Sip-specific monoclonal antibody (MAb) 5A12, which was used as a positive control, was described previously (8).

Top Abstract Introduction Materials and Methods Results Discussion References

 
Passive immunization. The potential of Sip-specific antibodies to protect neonates against infection was evaluated by passive administration of semipurified rabbit antibodies. After three injections with purified rSip protein, the reciprocal Sip-specific antibody titer of the rabbit antiserum was determined to be 5 x 10⁶. A total of three pregnant mice on day 16 of gestation were injected i.v. with 500 µl of partially purified rabbit antibodies. Two control pregnant mice received the same volume of either (i) partially purified antibodies collected from the same rabbit before its immunization or (ii) PBS. The pups were challenged s.c. between 24 and 48 h after birth with a lethal dose of 4 x 10⁴ CFU from the serotype Ia/c GBS strain C388/90. The survival data, representing monitoring of the number of survivors for 7 days after challenge, are presented as follows. None of the 19 pups from the control groups treated with rabbit preimmune serum (0 of 6 pups; n = 1 dam) or PBS (0 of 13 pups; n = 1 dam) survived the challenge, compared to 24 out of 25 pups (96%) whose dams (n = 3) had received the semipurified rabbit antibodies (P < 0.001 by Fisher's exact test against both control groups). Immunoblots confirmed the presence of rabbit Sip-specific antibodies in the sera of the pups collected 7 days after the GBS challenge (data not shown).

Active immunization. To evaluate the ability of Sip protein to protect neonates against GBS infection, female CD-1 mice were immunized s.c. with 20 µg of purified rSip protein with QuilA adjuvant. Control female mice were injected with PBS mixed with QuilA adjuvant. At the end of the immunization period, these mice were mated, and their pups were challenged with one of five serologically distinct GBS strains (Table 1). The strains used to challenge the pups were C388/90, ATCC 12401, NCS 251, NCS 437, and NCS 535, which were found to be of serotypes Ia/c, Ib, II/c, III/R, and V, respectively. A range of 75 to 98% of the pups born from immunized dams survived the GBS challenges, compared to 0 to 12% for the control groups. In all cases, the number of surviving pups in the immunized groups was shown, by Fisher's exact test, to be significantly different (P < 0.001) from the number of survivors recorded in the control groups. The number of survivors for each litter is presented in Table 2. When pooled together, the protection data indicated that 209 of the 233 (90%) pups born from dams immunized with purified rSip protein survived the GBS challenge, compared to only 6 of 167 (3%) of the pups born from control dams (P < 0.001).

View this table: [in this window] [in a new window]

TABLE 1. Survival of neonates born from female CD-1 mice immunized with purified recombinant Sip protein

View this table: [in this window] [in a new window]

TABLE 2. Determination of Sip-specific AU in sera from immunized dams and one pup from the corresponding litter

Sera from 20 of the 22 dams immunized with the rSip protein and 1 pup from the corresponding litter were collected the day the challenge was performed in order to evaluate by ELISA the presence of circulating anti-Sip antibodies, and the data are presented in Table 2. The mean ± standard deviation Sip-specific titers for the sera collected from Sip-immunized dams and corresponding pups were 345 ± 119 and 113 ± 40 AU/ml, respectively. The mean titer for the sera collected from Sip-immunized dams was approximately threefold higher than the mean titers that were determined for the corresponding pups. No Sip-specific antibody was detected at the lowest dilution tested (1/200) in the sera collected from dams and corresponding pups in the control groups. The ELISA results indicated that there were still Sip-specific antibodies (37 ± 10 AU/ml) present in the sera of pups born from Sip-immunized dams 64 days after challenge. No Sip-specific antibodies were detected in the sera collected 64 days after challenge from three pups that survived the GBS challenge, which were born from control dams. Immunoblots also confirmed the presence of Sip-specific antibodies in Sip-immunized dams and corresponding pups (Fig. 1).

View larger version (38K): [in this window] [in a new window]

FIG. 1. Immunoblots showing reactivity with purified rSip protein of antibodies present in sera collected on the day of GBS challenge. The experiment was performed with sera from dams immunized with purified rSip protein (lanes 1 to 3) or control mice (lanes 4 and 5) (A), neonates born from either Sip-immunized dams (lanes 1 to 7) or control dams (lanes 8 to 11) (B), and sera collected 7 days after challenge from surviving pups born from Sip-immunized dams (lanes 1 to 7) (C). The reactivity of the Sip-specific MAb 5A12 with the purified recombinant Sip is presented in lanes 6, 12, and 8 of panels A, B, and C, respectively.

Top Abstract Introduction Materials and Methods Results Discussion References

 
The importance of maternal antibody transfer for the protection of newborns human was clearly established (2, 4). Indeed, Baker et al. (2) demonstrated the existence of a correlation between maternal antibody deficiency at delivery and susceptibility to neonatal infection. These findings suggested that vaccination of pregnant women could become a very efficient prophylactic strategy to prevent GBS infection in neonates. Indeed, this approach could stimulate placental transfer of GBS-specific antibodies from the mother to the fetus, thus considerably increasing the level of protective antibodies present at the time of delivery (7).

Models to study transfer of IgG from the pregnant mother to the fetus and neonatal protection have been developed in the mouse (27), rat (9, 18), and primate (22). For this study, we selected the mouse neonatal model, since it is very well suited for testing in offspring the efficacy of antibodies acquired transplacentally from actively vaccinated dams (17). Indeed, in the absence of a mature immune system, protection in newborn pups can only be achieved via the acquisition of protective maternal antibodies. Furthermore, this model was recently used to evaluate the potency of different GBS conjugated CPS vaccines used for clinical phase 1 and 2 trials (19).

The neonate model was first designed to evaluate the functional activity of immune sera passively administered to pregnant dams on neonatal pup survival (23, 27). Indeed, Rodewald et al. (27) first reported that administration of a rabbit serum raised against GBS type III CPS vaccine passively protected 100% of the offspring. In this study, passive administration of Sip-specific rabbit antibodies to pregnant dams protected 96% of the pups against a lethal GBS challenge. The presence of circulating rabbit Sip-specific antibodies in the sera collected from these pups was confirmed by immunoblots (data not shown). As expected, no pup born from a dam that had received partially purified preimmune serum survived the GBS challenge. These results clearly demonstrate that Sip-specific antibodies produced in another animal species can efficiently cross the placenta to enter the fetal blood circulation and then confer protection to the newborn pups against GBS infection. Additional experiments should be conducted in order to determine the minimal amount of Sip-specific antibodies needed to confer the observed protection.

As previously presented, the Sip protein can be found at the surface of every GBS strains tested (26). Thus, maternal immunization with this protein could provide protective immunity that would not be restricted to a particular group of serologically related strains, as is the case for conjugated CPS vaccines (3, 12, 13). To demonstrate this, female CD-1 mice were immunized with purified rSip protein and mated. The newborn pups were then challenged with one of the serotype Ia/c, Ib, II, III, or V GBS strains (Table 1). A range of 75 to 98% of the pups born from immunized dams with the rSip protein survived the challenge with these five serologically different GBS strains. In an effort to understand the variation in the level of protection, we tried to establish a relationship between the number of survivors per litter and a variety of factors, such as the number of pups per litter, the mean body weight of the pups, the number of weeks between the last immunization and the bacterial challenge, and the number of hours between the time of delivery and challenge. Unfortunately, no correlation could be established. A higher number of survivors was recorded when the pups were challenged with serotypes Ia/c (98%) and V (96%). The lowest levels of protection were observed when pups were challenged with serotypes Ib (75%) and III (78%). ELISA (Table 2) and immunoblots (Fig. 1) indicated that maternal Sip-specific antibodies had crossed the placenta and were found in the sera from the pups. Detectable levels of Sip-specific antibodies were still present in the sera collected from pups 64 days after the challenge. These results suggest that maternal Sip-specific antibodies generated after vaccination could be present long enough in the blood circulation of newborns to confer protection against early- and late-onset GBS diseases. As was clearly established for conjugated CPS vaccine through clinical trials (5, 13), the levels of Sip-specific antibodies needed to confer protection still have to be determined.

In conclusion, the data presented in this report confirm that Sip-specific antibodies can cross the placenta in order to confer protection to the newborn pups against GBS diseases. Further studies are required to determine the particular surface epitopes that could play a role in antibody-mediated protective immunity.

 
This research was financially supported by Shire Biologics, Inc.

 
* Corresponding author. Mailing address: Unité de Recherche en Vaccinologie, Centre Hospitalier Universitaire de Québec, Pavillon CHUL, Édifice T-367, 2705 Boul. Laurier, Ste-Foy, Québec, Canada G1V 4G2. Phone:(418) 656-4141-6206. Fax: (418) 654-2280. E-mail: Denis.Martin{at}crchul.ulaval.ca.

Editor: E. I. Tuomanen

Top Abstract Introduction Materials and Methods Results Discussion References

 

1
1. Baker, C. J., M. S. Edwards, and D. L. Kasper. 1978. Immunogenicity of polysaccharides from type III, group B Streptococcus. J. Clin. Investig. 61:1107-1110.
2
2. Baker, C. J., and D. L. Kasper. 1976. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N. Engl. J. Med. 294:753-756.[Abstract]
3
3. Baker, C. J., and D. L. Kasper. 1985. Group B streptococcal vaccines. Rev. Infect. Dis. 7:458-467.[Medline]
4
4. Baker, C. J., D. L. Kasper, I. R. A. B. Tager, A. Paredes, S. Alpert, W. M. McCormack, and D. Goroff. 1977. Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus. J. Clin. Investig. 59:810-818.
5
5. Baker, C. J., L. C. Paoletti, M. R. Wessels, H. K. Guttormsen, M. A. Rench, M. E. Hickman, and D. L. Kasper. 1999. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J. Infect. Dis. 179:142-150.[CrossRef][Medline]
6
6. Baker, C. J., L. C. Paoletti, M. A. Rench, H. K. Guttormsen, V. J. Carey, M. E. Hickman, and D. L. Kasper. 2000. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. J. Infect. Dis. 182:1129-1138.[CrossRef][Medline]
7
7. Baker, C. J., M. A. Rench, M. S. Edwards, R. J. Carpenter, B. M. Hays, and D. L. Kasper. 1988. Immunization of pregnant women with a polysaccharide vaccine of group B Streptococcus. N. Engl. J. Med. 319:1180-1185.[Abstract]
8
8. Brodeur, B. R., M. Boyer, I. Charlebois, J. Hamel, F. Couture, C. R. Rioux, and D. Martin. 2000. Identification of group B streptococcal Sip protein, which elicits cross-protective immunity. Infect. Immun. 68:5610-5618.[Abstract/Free Full Text]
9
9. Ferrieri, P., B. Burke, and J. Nelson. 1980. Production of bacteremia and meningitis in infant rats with group B streptococcal serotypes. Infect. Immun. 27:1023-1032.[Abstract/Free Full Text]
10
10. Glezen, W. P., and M. Alpers. 1999. Maternal immunization. Clin. Infect. Dis. 28:219-224.[Medline]
11
11. Gravekamp, C., D. L. Kasper, L. C. Paoletti, and L. C. Madoff. 1999. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines. Infect. Immun. 67:2491-2496.[Abstract/Free Full Text]
12
12. Kasper, D. L., C. J. Baker, R. S. Baltimore, J. H. Crabb, G. Schiffman, and H. J. Jennings. 1979. Immunodeterminant specificity of human immunity to type III group B Streptococcus. J. Exp. Med. 149:327-339.[Abstract/Free Full Text]
13
13. Kasper, D. L., L. C. Paoletti, M. R. Wessels, H. K. Guttormsen, V. J. Carey, H. J. Jennings, and C. J. Baker. 1996. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J. Clin. Investig. 98:2308-2314.[Medline]
14
14. Lachenauer, C. S., D. L. Kasper, J. Shimada, Y. Ichiman, H. Ohtsuka, M. Kaku, L. C. Paoletti, P. Ferrieri, and L. C. Madoff. 1999. Serotypes VI and VIII predominate among group B streptococci isolated from pregnant Japanese women. J. Infect. Dis. 179:1030-1033.[CrossRef][Medline]
15
15. Lagergard, T., J. Shiloach, J. B. Robbins, and R. Schneerson. 1990. Synthesis and immunological properties of conjugates composed of group B Streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid. Infect. Immun. 58:687-694.[Abstract/Free Full Text]
16
16. Lancefield, R. C., M. McCarty, and W. N. Everly. 1975. Multiple mouse-protective antibodies directed against group B streptococci. Special reference to antibodies effective against protein antigens. J. Exp. Med. 142:165-179.[Abstract/Free Full Text]
17
17. Madoff, L. C., L. C. Paoletti, J. Y. Tai, and D. L. Kasper. 1994. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes. J. Clin. Investig. 94:286-292.
18
18. Moore, J. C., P. J. Muckett, and M. J. Hughes. 2001. Age-dependent presence of antibodies in rat dams, capable of conferring protection against group B Streptococcus infection in neonates. FEMS Microbiol. Lett. 202:125-127.[CrossRef][Medline]
19
19. Paoletti, L. C. 2001. Potency of clinical group B streptococcal conjugate vaccines. Vaccine 19:2118-2126.[CrossRef][Medline]
20
20. Paoletti, L. C., D. L. Kasper, F. Michon, J. DiFabio, H. J. Jennings, T. D. Tosteson, and M. R. Wessels. 1992. Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates. J. Clin. Investig. 89:203-209.
21
21. Paoletti, L. C., L. C. Madoff, and D. L. Kasper. 2000. Surface structures of group B Streptococcus important in human immunity, p.137-153. In V. A. Fischetti, R. P. Novick, J. J. Ferretti, D. A. Portnoy, and J. I. Rood (ed.), Gram-positive pathogens. ASM Press, Washington, D.C.
22
22. Paoletti, L. C., J. Pinel, R. C. Kennedy, and D. L. Kasper. 2000. Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate. J. Infect. Dis. 181:653-658.[CrossRef][Medline]
23
23. Paoletti, L. C., J. Pinel, A. K. Rodewald, and D. L. Kasper. 1997. Therapeutic potential of human antisera to group B streptococcal glycoconjugate vaccines in neonatal mice. J. Infect. Dis. 175:1237-1239.[Medline]
24
24. Paoletti, L. C., M. R. Wessels, F. Michon, J. DiFabio, H. J. Jennings, and D. L. Kasper. 1992. Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine. Infect. Immun. 60:4009-4014.[Abstract/Free Full Text]
25
25. Paoletti, L. C., M. R. Wessels, A. K. Rodewald, A. A. Shroff, H. J. Jennings, and D. L. Kasper. 1994. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine. Infect. Immun. 62:3236-3243.[Abstract/Free Full Text]
26
26. Rioux, S., D. Martin, H.-W. Ackermann, J. Dumont, J. Hamel, and B. R. Brodeur. 2001. Localization of surface immunogenic protein on group B Streptococcus. Infect. Immun. 69:5162-5165.[Abstract/Free Full Text]
27
27. Rodewald, A. K., A. B. Onderdonk, H. B. Warren, and D. L. Kasper. 1992. Neonatal mouse model of group B streptococcal infection. J. Infect. Dis. 166:635-639.[Medline]
28
28. Schuchat, A. 1998. Epidemiology of group B streptococcal disease in the United States: shifting paradigms. Clin. Microbiol. Rev. 11:497-513.[Abstract/Free Full Text]
29
29. Stalhammar-Carlemalm, M., L. Stenberg, and G. Lindahl. 1993. Protein Rib: a novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections. J. Exp. Med. 177:1593-1603.[Abstract/Free Full Text]
30
30. Wessels, M. R., L. C. Paoletti, D. L. Kasper, J. L. DiFabio, F. Michon, K. Holme, and H. J. Jennings. 1990. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J. Clin. Investig. 86:1428-1433.
31
31. Wessels, M. R., L. C. Paoletti, J. Pinel, and D. L. Kasper. 1995. Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J. Infect. Dis. 171:879-884.[Medline]
32
32. Wessels, M. R., L. C. Paoletti, A. K. Rodewald, F. Michon, J. DiFabio, H. J. Jennings, and D. L. Kasper. 1993. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine. Infect. Immun. 61:4760-4766.[Abstract/Free Full Text]

---

Infection and Immunity, September 2002, p. 4897-4901, Vol. 70, No. 9
0019-9567/02/$04.00+0     DOI: 10.1128/IAI.70.9.4897-4901.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Nobbs, A. H., Lamont, R. J., Jenkinson, H. F. (2009). Streptococcus Adherence and Colonization. Microbiol. Mol. Biol. Rev. 73: 407-450 [Abstract] [Full Text]  
• Doro, F., Liberatori, S., Rodriguez-Ortega, M. J., Rinaudo, C. D., Rosini, R., Mora, M., Scarselli, M., Altindis, E., D'Aurizio, R., Stella, M., Margarit, I., Maione, D., Telford, J. L., Norais, N., Grandi, G. (2009). Surfome Analysis as a Fast Track to Vaccine Discovery: IDENTIFICATION OF A NOVEL PROTECTIVE ANTIGEN FOR GROUP B STREPTOCOCCUS HYPERVIRULENT STRAIN COH1. Mol. Cell. Proteomics 8: 1728-1737 [Abstract] [Full Text]  
• Yang, H.-H., Mascuch, S. J., Madoff, L. C., Paoletti, L. C. (2008). Recombinant Group B Streptococcus Alpha-Like Protein 3 Is an Effective Immunogen and Carrier Protein. CVI 15: 1035-1041 [Abstract] [Full Text]  
• Seepersaud, R., Hanniffy, S. B., Mayne, P., Sizer, P., Le Page, R., Wells, J. M. (2005). Characterization of a Novel Leucine-Rich Repeat Protein Antigen from Group B Streptococci That Elicits Protective Immunity. Infect. Immun. 73: 1671-1683 [Abstract] [Full Text]  
• Lindahl, G., Stalhammar-Carlemalm, M., Areschoug, T. (2005). Surface Proteins of Streptococcus agalactiae and Related Proteins in Other Bacterial Pathogens. Clin. Microbiol. Rev. 18: 102-127 [Abstract] [Full Text]  
• Slotved, H.-C., Elliott, J., Thompson, T., Konradsen, H. B. (2003). Latex Assay for Serotyping of Group B Streptococcus Isolates. J. Clin. Microbiol. 41: 4445-4447 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Martin, D. Articles by Brodeur, B. R. Search for Related Content PubMed PubMed Citation Articles by Martin, D. Articles by Brodeur, B. R.